{
    "clinical_study": {
        "@rank": "4744", 
        "arm_group": [
            {
                "arm_group_label": "Estradiol", 
                "arm_group_type": "Experimental", 
                "description": "Intravaginal self-administration of study medication once daily for 14 days."
            }, 
            {
                "arm_group_label": "Reference: Estradiol", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravaginal self-administration of study medication once daily for 14 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravaginal self-administration of study medication once daily for 14 days."
            }
        ], 
        "brief_summary": {
            "textblock": "Estradiol vaginal tablet is a tablet which hydrates upon contact with moisture, releasing\n      17\u00df-estradiol.\n\n      The estradiol in estradiol vaginal tablet is chemically and biologically identical to the\n      endogenous human estradiol and is therefore classified as a human estrogen.\n\n      The purpose of this study is to demonstrate clinical endpoint bioequivalence of SPIL's\n      Estradiol vaginal tablet, 10mcg estradiol to the reference listed drug (Vagifem\u00ae)which is\n      approved and marketed in the US."
        }, 
        "brief_title": "Efficacy and Safety Of Spil's Estradiol Vaginal Tablet", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vulvar Atrophy", 
            "Vaginal Atrophy"
        ], 
        "condition_browse": {
            "mesh_term": "Atrophy"
        }, 
        "detailed_description": {
            "textblock": "Estradiol vaginal tablet is indicated for use in the treatment of symptoms of atrophic\n      vaginitis due to estrogen deficiency.\n\n      This is a randomized, observer blind, parallel groups, active and placebo controlled study\n      to test the clinical endpoint bioequivalence of test product (Estradiol vaginal tablet,\n      10mcg of Sun Pharmaceutical Industries Ltd. India) relative to reference (Vagifem\u00ae,\n      Estradiol vaginal tablet, 10mcg estradiol of Novo Nordisk) in treatment of vulvar and\n      vaginal atrophy.\n\n      The patients will be administered with one tablet intravaginally daily for 14 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal woman\n\n          -  At least one subject-self-assessed moderate to severe symptom of vulvar and vaginal\n             atrophy\n\n          -  \u2264 5% superficial cells on vaginal smear cytology\n\n          -  Vaginal pH > 5.0\n\n        Exclusion Criteria:\n\n          -  Consumption of estrogen alone or estrogen/progestin containing drug products.\n\n          -  Allergy to estradiol or related products\n\n          -  History of breast cancer and significant risk factors for endometrial cancer\n\n          -  Abnormal genital bleeding"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "405", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753102", 
            "org_study_id": "CLR_10_19", 
            "secondary_id": "CTRI/2012/09/002983"
        }, 
        "intervention": {
            "arm_group_label": [
                "Estradiol", 
                "Reference: Estradiol"
            ], 
            "description": "one tablet will be inserted daily for 14 days", 
            "intervention_name": "Estradiol", 
            "intervention_type": "Drug", 
            "other_name": "Vagifem"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Estradiol", 
            "Vulvar atrophy", 
            "vaginal atrophy"
        ], 
        "lastchanged_date": "December 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pune", 
                    "country": "India", 
                    "state": "Maharashtra", 
                    "zip": "411004"
                }, 
                "name": "Biniwale Clinic Pvt. Ltd,"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "3", 
        "official_title": "EFFICACY AND SAFETY OF SPIL'S ESTRADIOL VAGINAL TABLET, 10 MCG ESTRADIOL IN SUBJECTS WITH VULVAR AND VAGINAL ATROPHY: A RANDOMIZED, OBSERVER BLIND, PARALLEL GROUPS, ACTIVE AND PLACEBO CONTROLLED, CLINICAL ENDPOINT BIOEQUIVALENCE STUDY", 
        "overall_contact": {
            "last_name": "Atul Raut, MD, PhD", 
            "phone": "91 22 66455645", 
            "phone_ext": "752"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Vaginal pH", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Each subject will specify identified most bothersome symptoms vaginal dryness, vaginal and/or vulvar irritation/ itching, dysuria, vaginal pain associated with sexual activity, vaginal bleeding associated with sexual activity) and self-evaluate the symptom on a pre-defined scale", 
            "measure": "Symptoms of vulvar and vaginal atrophy", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "source": "Sun Pharmaceutical Industries Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Pharmaceutical Industries Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}